AC Immune (NASDAQ: ACIU) director reports initial Form 3 holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
AC Immune SA director Roy Ervin Twyman reported his initial holdings on a Form 3. He directly holds 75,988 common shares, including 49,988 common shares underlying outstanding restricted share units. He also holds multiple share options over common shares with exercise prices between $1.84 and $7.23, expiring from 2029 through 2035.
According to the footnotes, at least one share option grant is fully vested and another will fully vest on June 17, 2026, highlighting a mix of already exercisable and time-based equity awards.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Twyman Roy Ervin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 36,932 shares (Direct);
Common Shares — 75,988 shares (Direct)
Footnotes (1)
- Includes 49,988 common shares underlying outstanding restricted share units. The share option is fully vested. The share option will fully vest on June 17, 2026.
FAQ
What does the Form 3 filing for AC Immune (ACIU) disclose about Roy Ervin Twyman?
The Form 3 shows that director Roy Ervin Twyman reported his initial ownership in AC Immune. It details his direct holdings of common shares and several share option awards with different exercise prices and expiration dates, establishing his baseline equity position as an insider.
What equity awards are reported for Roy Ervin Twyman in the AC Immune (ACIU) Form 3?
The filing lists several share options to buy AC Immune common shares with exercise prices ranging from $1.84 to $7.23. These options have expiration dates between 2029 and 2035, indicating long-dated incentives aligned with the company’s longer-term performance horizon.
Does the AC Immune (ACIU) Form 3 show any recent insider buying or selling by Roy Ervin Twyman?
No buying or selling activity is indicated; the entries are labeled as holdings. The Form 3 functions as an initial ownership statement, summarizing Twyman’s existing common share and option positions rather than reporting new market transactions or changes in his stake.